Skip to content
Yog Pharma
Pain and inflammationNSAID (oxicam)

Meloxicam is an NSAID (oxicam) indicated for osteoarthritis and rheumatoid arthritis. We supply it to US manufacturers of tablets, capsules and oral suspension.

CAS71125-38-7351.4 g/molC14H13N3O4S2
2D structure of Meloxicam.

Data from PubChem (CID 54677470) and FDA’s substance registry

CAS number

71125-38-7

Molecular formula

C14H13N3O4S2

Molecular weight

351.4g/mol

FDA UNII

IUPAC name

4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1lambda6,2-benzothiazine-3-carboxamide

InChIKey

ZRVUJXDFFKFLMG-UHFFFAOYSA-N

Appearance
Pale yellow powder.
Solubility
Practically insoluble in water, with higher solubility in strong acids and bases. Very slightly soluble in methanol.

Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.

Worth settling with your inquiry

Micronized material is typical for tablets and oral suspension.

On the US market

Reference product
MobicNDA 020938
Approved ANDAs
15 with a marketed product
Approved forms and strengths
  • Tablet 7.5 mg, 15 mg
  • Capsule 5 mg, 10 mg
  • Oral suspension 7.5 mg/5 mL
  • Injection 30 mg/mL

Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.

Grade

USP or Ph. Eur. where a monograph exists, or your own specification.

Quantities

From development quantities for formulation work to commercial supply.

Packaging

To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.

Regulatory filings

US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.

Documents available with a quote

  • Specification and certificate of analysis
  • Safety data sheet
  • Method of analysis
  • DMF letter of authorization, where a US DMF is filed
  • GMP certificate and inspection history of the site
  • Residual solvents and elemental impurities statements
  • Nitrosamine risk assessment
  • TSE/BSE statement

Need something else for your QA file? Email info@yogpharma.com